The Union Government has stated that there is no shortage of important tuberculosis (TB) medicines in response to questions made in Parliament regarding whether key treatments, such as rifampicin and ethambutol, were running low in central and state warehouses. These two medications form the foundation of tuberculosis treatment: rifampicin is a potent antibiotic that kills tuberculosis bacteria, and ethambutol is used to prevent the bacterium from developing resistance. Both are part of the standard first-line regimen used around the globe. 

The assuance was given in the Rajya Sabha on December 9, 2025, when Member of Parliament Rajani Ashokrao Patil enquired whether delays in tender finalisation had impacted supply under the National TB Elimination Programme (NTEP). In a written response, Minister of State for Health Anupriya Patel stated, "There are no shortages of any key anti-TB drugs, including Rifampicin and Ethambutol, in the Central and State warehouses." 

This clarification comes at a time when India continues to have the world's highest tuberculosis burden, making ongoing access to medications a crucial public health priority. Even small supply shortages can interrupt therapy, promote transmission, and fuel drug-resistant tuberculosis, a more severe and costly form of the illness. 

According to the minister, a rate contract model—a centralised system that locks in rates and manufacturer supply commitments—has been formed for 2025-27, which includes innovative and shorter treatment regimes. She said that the government had secured "adequate buffer" stocks, which are medications stored in reserve to prevent shortages during delays or abrupt surges in demand. 

To enhance the supply chain, the Health Ministry proposed a number of initiatives. These include the timely submission of indents (formal requests from states for the next batch of pharmaceuticals) and real-time stock tracking via the Drugs & Vaccines Distribution Management System (DVDMS). The DVDMS interface enables officials to track every step of the drug's path, from purchase to consumption, using a simple dashboard. 

The ministry also noted routine physical stock verification by teams at the national, state, and district levels, as well as ongoing supervision and evaluations. Coordination with suppliers has been strengthened to ensure the timely supply of medications, diagnostics, and reagent kits, all of which are critical for accurate tuberculosis diagnosis and treatment. 

Public-health experts point out that, while these actions indicate increased oversight, consistent execution remains critical. India's TB elimination ambitions rely not just on drug availability but also on dependable delivery methods that reach patients in distant places where logistical delays are more likely. For families who rely on the public system, even a few days of delay can result in treatment discontinuation. 

Currently, the government's message is that the system is stable. The following months will see if the enhanced supply chain can keep up with India's ambitious TB elimination ambitions.